ATEROSKLEROZ RIVOJLANISHIDA LIPID ALMASHINUVI BUZILISHLARINING O‘RNI VA MEXANIZMLARI
Keywords:
ateroskleroz, dislipidemiya, endotelial disfunksiya, oksidlangan past zichlikdagi lipoproteinlar (oxPZL), ko'pik hujayralar, surunkali yallig'lanish, aterosklerotik blyashka.Abstract
Ateroskleroz va yurak-qon tomir kasalliklari global o'lim ko'rsatkichlarining asosiy sababchisi bo'lib qolmoqda. Ushbu patologik jarayonning fundamental asosida lipid almashinuvi buzilishlari — dislipidemiya yotadi. Mazkur maqolada dislipidemiya turlarining aterogenlik salohiyati, endotelial disfunksiya mexanizmlari, past zichlikdagi lipoproteinlarning (PZL) oksidlanishi va surunkali yallig'lanish kaskadining aterosklerotik blyashka shakllanishidagi roli batafsil ko'rib chiqilgan. Qon plazmasida PZL va triglitseridlarning ortishi hamda yuqori zichlikdagi lipoproteinlarning (YZL) kamayishi subendotelial bo'shliqda lipidlar infiltratsiyasi va oksidlovchi stressga olib kelishi ko'rsatib o'tilgan. Shuningdek, makrofaglar tomonidan oksidlangan PZL ning scavenger retseptorlari orqali yutilishi natijasida ko'pik hujayralarning shakllanishi, yallig'lanish mediatorlari sintezining faollashuvi va natijada beqaror aterosklerotik blyashkalarning yuzaga kelishi bosqichma-bosqich tahlil qilingan. Xulosa o'rnida, o'tkir qon-tomir asoratlarini (miokard infarkti, insult) kamaytirish maqsadida lipid profilini muntazam nazorat qilish, sog'lom turmush tarzi va zamonaviy gipolipidemik terapiyani (statinlar, ezetimib, PCSK9 ingibitorlari) kompleks qo'llashning klinik ahamiyati yoritib berilgan.
References
Libby, P. (2021). The changing landscape of atherosclerosis. Nature Reviews Cardiology, 18(5), 331–345.
Borén, J., Williams, K. J., & Tabas, I. (2020). Lipid metabolism and atherosclerosis: Current understanding and future directions. Nature Reviews Cardiology, 17(11), 701–718.
Ference, B. A., Ginsberg, H. N., Graham, I., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. European Heart
Journal, 38(32), 2459–2472.
Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2019). 2018 Guideline on the management of blood cholesterol. Circulation, 139(25), e1082–e1143.
Hansson, G. K. (2005). Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine, 352(16), 1685–1695.
Tabas, I., García-Cardeña, G., & Owens, G. K. (2015). Recent insights into the cellular biology of atherosclerosis. Cell Metabolism, 22(6), 860–874.
Mach, F., Baigent, C., Catapano, A. L., et al. (2019). 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 41(1), 111–188.
World Health Organization. (2023). Cardiovascular diseases (CVDs): Key facts. Geneva: WHO.
Ridker, P. M., Everett, B. M., Thuren, T., et al. (2017). Anti-inflammatory therapy with canakinumab for atherosclerotic disease. New England Journal of Medicine, 377(12), 1119–1131.
Ross, R. (1999). Atherosclerosis — an inflammatory disease. New England Journal of Medicine, 340(2), 115–126.
Goldstein, J. L., & Brown, M. S. (2015). A century of cholesterol and coronaries: From plaques to genes to statins. Cell, 161(1), 161–172.
Lusis, A. J. (2000). Atherosclerosis. Nature, 407(6801), 233–241.
Libby, P., Buring, J. E., Badimon, L., et al. (2019). Atherosclerosis. Nature Reviews Disease Primers, 5(1), 56.
Chapman, M. J., Ginsberg, H. N., Amarenco, P., et al. (2011). Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk. European Heart Journal, 32(11), 1345–1361.
Baigent, C., Blackwell, L., Emberson, J., et al. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol. Lancet, 376(9753), 1670–1681
Baigent, C., Blackwell, L., Emberson, J., et al. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol. The Lancet, 376(9753), 1670–1681. https://doi.org/10.1016/S0140-6736(10)61350-5
Borén, J., Williams, K. J., & Tabas, I. (2020). Lipid metabolism and atherosclerosis: Current understanding and future directions. Nature Reviews Cardiology, 17(11), 701–718. https://doi.org/10.1038/s41569-020-0364-0
Chapman, M. J., Ginsberg, H. N., Amarenco, P., et al. (2011). Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk. European Heart Journal, 32(11), 1345–1361. https://doi.org/10.1093/eurheartj/ehr112
Ference, B. A., Ginsberg, H. N., Graham, I., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. European Heart Journal, 38(32), 2459–2472. https://doi.org/10.1093/eurheartj/ehx144
Goldstein, J. L., & Brown, M. S. (2015). A century of cholesterol and coronaries: From plaques to genes to statins. Cell, 161(1), 161–172. https://doi.org/10.1016/j.cell.2015.01.036
Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2019). 2018 guideline on the management of blood cholesterol. Circulation, 139(25), e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625
Hansson, G. K. (2005). Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine, 352(16), 1685–1695. https://doi.org/10.1056/NEJMra043430
Libby, P. (2021). The changing landscape of atherosclerosis. Nature Reviews Cardiology, 18(5), 331–345. https://doi.org/10.1038/s41569-020-00432-y
Libby, P., Buring, J. E., Badimon, L., et al. (2019). Atherosclerosis. Nature Reviews Disease Primers, 5(1), 56. https://doi.org/10.1038/s41572-019-0106-z
Lusis, A. J. (2000). Atherosclerosis. Nature, 407(6801), 233–241. https://doi.org/10.1038/35025203
Mach, F., Baigent, C., Catapano, A. L., et al. (2019). 2019 ESC/EAS guidelines for the management of dyslipidaemias. European Heart Journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455
Ridker, P. M., Everett, B. M., Thuren, T., et al. (2017). Anti-inflammatory therapy with canakinumab for atherosclerotic disease. New England Journal of Medicine, 377(12), 1119–1131. https://doi.org/10.1056/NEJMoa1707914
Ross, R. (1999). Atherosclerosis—an inflammatory disease. New England Journal of Medicine, 340(2), 115–126. https://doi.org/10.1056/NEJM199901143400207
Tabas, I., García-Cardeña, G., & Owens, G. K. (2015). Recent insights into the cellular biology of atherosclerosis. Cell Metabolism, 22(6), 860–874. https://doi.org/10.1016/j.cmet.2015.07.014
World Health Organization. (2023). Cardiovascular diseases (CVDs): Key facts. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds





